Skip to main content

Advertisement

SpringerLink
Log in

Cutaneous Manifestations of Connective Tissue Disease in the Inpatient Setting

  • Hospital-based Dermatology (D Kroshinsky, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

We review the cutaneous manifestations of connective tissue disease (CTD) in the inpatient setting. Dermatologists are often consulted by the admitting team to help with skin signs of CTD to reach a diagnosis in new patients, as well as in managing catastrophic cutaneous complications of CTD. Therefore, we discuss here the common and characteristic cutaneous manifestations. Also, we discuss the catastrophic cutaneous complications of CTD and how to manage them.

Recent Findings

We review and summarize the current literature of characteristic cutaneous manifestations and cutaneous emergencies of CTD. We present the most recent and evidence-based management of these cutaneous manifestations.

Summary

CTD in the inpatient setting represents both the most subtle presentations and the most severe. Dermatologic review can be invaluable in aiding the managing team reach a firm diagnosis as well as providing the current knowledge of how to manage these cutaneous problems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Yildirim Cetin G, Sayar H, Ozkan F, et al. A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature. Lupus. 2013;22(8):839–46.

    Article  CAS  PubMed  Google Scholar 

  2. Torchia D, Romanelli P, Kerdel FA. Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus. J Am AcadDermatol. 2012;67(3):417–21.

    Article  Google Scholar 

  3. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16(6):475–93.

    Article  PubMed  Google Scholar 

  4. Ranario JS, Smith JL. Bullous lesions in a patient with systemic lupus erythematosus. J Clin Aesthet Dermatol. 2014;7(9):44–9.

    PubMed  PubMed Central  Google Scholar 

  5. Lee A, Batra P, Furer V, et al. Rowell syndrome (systemic lupus erythematosus + erythema multiforme). Dermatol Online J. 2009;15(8):1.

    PubMed  Google Scholar 

  6. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study J Invest Dermatol. 2008;128(1):35–44.

    Article  CAS  PubMed  Google Scholar 

  7. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–7.

    Article  CAS  PubMed  Google Scholar 

  8. Schotland P, Bojunga N, Zien A, et al. Improving drug safety with a systems pharmacology approach. Eur J Pharm Sci. 2016;94:84–92.

  9. Ziemer M, Kardaun SH, Liss Y, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012;166(3):575–600.

    Article  CAS  PubMed  Google Scholar 

  10. Vazquez-Sanabria IL, Mercado-Seda R, Varela-Rosario N, et al. Efficacy of intravenous immunoglobulins in a patient with systemic lupus erythematosus presenting with Stevens-Johnson syndrome. BMJ Case Rep. 2015; doi:10.1136/bcr-2015-211157.

  11. Lateef A, Tan KB, Lau TC. Acute generalized exanthematouspustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. ClinRheumatol. 2009;28(12):1449–52. doi:10.1007/s10067-009-1262.

    Google Scholar 

  12. Cameron MC, Word AP, Dominguez A. Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. Dermatol Online J. 2014;20(11). pii:13030/qt1q90q0h5

  13. Callaly EL, FitzGerald O, Rogers S. Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis. ClinExpDermatol. 2008;33(5):572–4. doi:10.1111/j.1365-2230.2008.02704.x.

    CAS  Google Scholar 

  14. Leckie MJ, Rees RG. Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. Rheumatology (Oxford). 2002;41(4):473–4.

    Article  CAS  Google Scholar 

  15. Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol. 2001;26(5):457–8.

    Article  CAS  PubMed  Google Scholar 

  16. Chowdhury AC, Misra DP, Patro PS, et al. Toxic epidermal necrolysis due to therapy with cyclophosphamide and mesna. A case report of a patient with seronegative rheumatoid arthritis and rheumatoid vasculitis. Z Rheumatol. 2016;75(2):200–2. doi:10.1007/s00393-015-1632-z.

    Article  CAS  PubMed  Google Scholar 

  17. Sasak G, Zemheri E, Ozkok A. Toxic epidermal necrolysis due to cyclophosphamide. Clin Exp Nephrol. 2016;20(4):660–1. doi:10.1007/s10157-015-1181-4.

    Article  PubMed  Google Scholar 

  18. Patel MP, Kute VB, Vanikar AV, et al. Cyclophosphamide-induced toxic epidermal necrolysis: vigilance needed. Clin Kidney J. 2014;7(3):323–4. doi:10.1093/ckj/sfu027.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Assier-Bonnet H, Aractingi S, Cadranel J, et al. Stevens–Johnson syndrome induced by cyclophosphamide: report of two cases. Br J Dermatol. 1996;135(5):864–6.

    Article  CAS  PubMed  Google Scholar 

  20. Didona D, Paolino G, Garcovich S, et al. Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. J EurAcadDermatolVenereol. 2015; doi:10.1111/jdv.13330.

    Google Scholar 

  21. Fallon MJ, Heck JN. Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy. J Oncol Pharm Pract. 2015;21(5):388–92. doi:10.1177/1078155214533368.

    Article  CAS  PubMed  Google Scholar 

  22. Lowndes S, Darby A, Mead G, et al. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002;13(12):1948–50.

    Article  CAS  PubMed  Google Scholar 

  23. Allen KP, Funk AJ, Mandrell TD. Toxic epidermal necrolysis in two rhesus macaques (MacacaMulatta) after administration of rituximab. Comp Med. 2005;55:377–81.

    CAS  PubMed  Google Scholar 

  24. Kuehn BM. FDA: acetaminophen may trigger serious skin problems. JAMA. 2013;310(8):785. doi:10.1001/jama.2013.276938.

    Article  CAS  PubMed  Google Scholar 

  25. Angadi SS, Karn A. Ibuprofen induced Stevens-Johnson syndrome—toxic epidermal necrolysis in Nepal. Asia Pac Allergy. 2016;6(1):70–3. doi:10.5415/apallergy.2016.6.1.70.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yu Y, Lizhong D, Pan J, et al. A 10-year retrospective study of neonatal lupus erythematous in China. Asian Pac J Allergy Immunol. 2016;34(2):174–8.

    PubMed  Google Scholar 

  27. Yi-qun LI, Qian WANG, Yan LUO, et al. Neonatal lupus erythematosus: a review of 123 cases in China. Int J Rheum Dis. 2015;18:761–7.

    Article  Google Scholar 

  28. Buyon JP, Clancy RM. Neonatal lupus: basic research and clinical perspectives. Rheum Dis Clin N Am. 2005;31(2):299–313.

    Article  Google Scholar 

  29. Lee LA. The clinical spectrum of neonatal lupus. Arch Dermatol Res. 2009;301(1):107–10.

    Article  PubMed  Google Scholar 

  30. Cervera R, Piette JC, Font J, Euro-Phospholipid Project Group, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.

    Article  PubMed  Google Scholar 

  31. • Cervera R, Serrano R, Pons-Estel GJ, Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies), et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011–8. This is the largest recent cohort study assessing the prevalence of the main causes of morbidity and mortality in antiphospholipid antibody syndrome.

    Article  CAS  PubMed  Google Scholar 

  32. Pinto-Almeida T, Caetano M, Sanches M, et al. Cutaneous manifestations of antiphospholipid syndrome: a review of the clinical features, diagnosis and management. Acta Reumatol Port. 2013;38:10–8.

    PubMed  Google Scholar 

  33. Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol. 2014;3(1):9–17.

    PubMed  PubMed Central  Google Scholar 

  34. Frances C. Dermatological manifestations of Hughes’ antiphospholipid antibody syndrome. Lupus. 2010;19(9):1071–7.

    Article  CAS  PubMed  Google Scholar 

  35. Asherson RA, Espinosa G, Cervera R, et al. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol. 2002;8(3):157–65.

    Article  PubMed  Google Scholar 

  36. Jeong HS, Dominguez AR. Calciphylaxis: controversies in pathogenesis, diagnosis and treatment. Am J Med Sci. 2016;351(2):217–27.

    Article  PubMed  Google Scholar 

  37. Huilaja L, Turpeinen M, Tokola H, et al. Warfarin-induced calciphylaxis in patients with normal renal function. J Clin Pharm Ther. 2016;41(4):449–52.

    Article  CAS  PubMed  Google Scholar 

  38. Vedvyas C, Winterfield LS, Vleugels RA. Calciphylaxis: a systematic review of existing and emerging therapies. J Am Acad Dermatol. 2012;67(6):e253–60.

    Article  PubMed  Google Scholar 

  39. Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133–46.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Strazzula L, Nigwekar SU, Steele D, et al. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol. 2013;149(8):946–9.

    Article  PubMed  Google Scholar 

  41. Callen JP. Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep. 2010;12:192–7.

    Article  PubMed  Google Scholar 

  42. Muro Y, Sugiura K, Akiyama M. Cutaneous manifestations in dermatomyositis: key clinical and serological features—a comprehensive review. Clin Rev Allergy Immunol. 2015; doi:10.1007/s12016-015-8496-5.

    Google Scholar 

  43. Sallum A, Pivato F, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr. 2008;84:68–74.

    Article  Google Scholar 

  44. Saini I, Kalaivani M, Kabra SK. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int. 2016;36(7):961–5.

    Article  CAS  PubMed  Google Scholar 

  45. Sanner H, Gran JT, Sjaastad I, et al. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford). 2009;48:1541–7.

    Article  Google Scholar 

  46. Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;62:63–72.

    Article  Google Scholar 

  47. Galimberti F, Li Y, Fernandez AP. Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis. J Am Acad Dermatol. 2015;73(1):174–6.

    Article  PubMed  Google Scholar 

  48. Marco Puche A, CalvoPenades I, Lopez MB. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. ClinExpRheumatol. 2010;28(1):135–40.

    CAS  Google Scholar 

  49. Boulter EL, Beard L, Ryder C, et al. Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis. PediatrRheumatol Online J. 2011;9(Suppl 1):O29.

    Google Scholar 

  50. Balin SJ, Wetter DA, Andersen LK, et al. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996- 2009. Arch Dermatol. 2012;148:455–62.

    Article  CAS  PubMed  Google Scholar 

  51. Bair B, Fivenson D. A novel treatment for ulcerative calcinosis cutis. J Drugs Dermatol. 2011;10:1042–4.

    PubMed  Google Scholar 

  52. Smith GP. Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease. J Am Acad Dermatol. 2013;69(3):e146–7.

    Article  CAS  PubMed  Google Scholar 

  53. Del Barrio-Díaz P, Moll-Manzur C, Álvarez-Veliz S, et al. Topical sodium metabisulfite for the treatment of calcinosis cutis: a promising new therapy. Br J Dermatol. 2016; doi:10.1111/bjd.14412.

    PubMed  Google Scholar 

  54. Sultan-Bichat N, Menard J, Perceau G, et al. Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. J Am Acad Dermatol. 2012;66(3):424–9.

    Article  PubMed  Google Scholar 

  55. Reiter N, El-Shabrawi L, Leinweber B, et al. Calcinosis cutis: part II. Treatment options. J Am AcadDermatol. 2011;65(1):15–22; quiz 23–4.

  56. Tolosa-Vilella C, Morera-Morales ML, Simeón-Aznar CP, RESCLE Investigators, Autoimmune Diseases Study Group (GEAS) et al.. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Semin Arthritis Rheum. 2016.

  57. • Wirz EG, Jaeger VK, Allanore Y, EUSTAR coauthors, et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis. 2016;75(7):1285–92. This 10-year longitudinal study maps the onset and identify the risk factors for skin sclerosis and digital ulcers in patients with systemic sclerosis.

    Article  PubMed  Google Scholar 

  58. Desbois AC, Cacoub P. Systemic sclerosis: an update in 2016. Autoimmun Rev. 2016;15(5):417–26.

    Article  PubMed  Google Scholar 

  59. Hughes M, Herrick AL. Raynaud’s phenomenon. Best Pract Res Clin Rheumatol. 2016;30(1):112–32.

    Article  PubMed  Google Scholar 

  60. Volkmann ER, Furst DE. Management of systemic sclerosis-related skin disease: a review of existing and experimental therapeutic approaches. Rheum Dis Clin N Am. 2015;41(3):399–417.

    Article  Google Scholar 

  61. Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology (Oxford). 2016.

  62. De Cata A, Inglese M, Molinaro F, et al. Digital ulcers in scleroderma patients: a retrospective observational study. Int J Immunopathol Pharmacol. 2016;29(2):180–7.

    Article  CAS  PubMed  Google Scholar 

  63. Brueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis. 2010;69(8):1475–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32–8.

    Article  CAS  PubMed  Google Scholar 

  65. Neumeister MW. Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg Am. 2010;35(12):2085–92.

    Article  PubMed  Google Scholar 

  66. Valenzuela A, Baron M, Herrick AL, et al. Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: a Scleroderma Clinical Trials Consortium study. Semin Arthritis Rheum. 2016.46:344–349.

  67. Morardet L, Avouac J, Sammour M, et al. Late nailfold videocapillaroscopy pattern associated with hand calcinosis and acro-osteolysis in systemic sclerosis. Arthritis Care Res (Hoboken). 2016;68(3):366–73.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. King Khalid University, Abha, Saudi Arabia

    Yahya Argobi

  2. 202 Katahdin Drive, Lexington, MA, 02421, USA

    Yahya Argobi

  3. Department of Dermatology, MGH, Boston, MA, USA

    Gideon P. Smith

Authors
  1. Yahya Argobi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gideon P. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yahya Argobi.

Ethics declarations

Conflict of Interest

Dr. Smith reports being a consultant for Cipher, for evaluation of a feasibility clinical study—not performed, outside the submitted work.

Dr. Argobi has no conflicts of interest.

Patient consent

all patients signed a consent form that includes a paragraph stating that images may beused for the purposes of publication which we then scaned into their medical record.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hospital-based Dermatology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Argobi, Y., Smith, G.P. Cutaneous Manifestations of Connective Tissue Disease in the Inpatient Setting. Curr Derm Rep 6, 77–84 (2017). https://doi.org/10.1007/s13671-017-0180-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-017-0180-y

Keywords

Search

Navigation